Biotech News

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Acrivon Therapeutics (ACRV)Acrivon Therapeutics2026-06-25 13:46 ESTClinical readout

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need

Open original release

Related news

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

ACRVAcrivon Therapeutics2026-06-25 13:46 EST

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Acrivon Therapeutics

Acrivon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ACRVAcrivon Therapeutics2026-06-26 07:29 EST

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

ACRVAcrivon Therapeutics2026-06-26 07:29 EST

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

ACRVAcrivon Therapeutics2026-06-26 07:29 EST

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

ACRVAcrivon Therapeutics2026-06-26 07:29 EST

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

ACRVAcrivon Therapeutics2026-06-26 07:29 EST

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States